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Clinical and Biologic Relevance of Immunologic Marker Studies in Childhood 
Acute Lymphoblastic Leukemia 
By Ching-Hon Pui, Frederick G. Behm, and William M. Crist 
YBRIDOMA  TECHNOLOGY,  developed  in  the  H  mid-1 970s by Kohler and Milstein,’ made it possible 
to produce virtually limitless quantities of highly specific 
monoclonal antibodies (MoAbs)  that recognize distinct epi- 
topes of cellular antigens. This advance, combined with mo- 
lecular probes that identify antigen-receptor  gene rearrange- 
ments, has led to valuable insights into normal lymphocyte 
differentiation and the cellular origins of lymphoid leuke- 
mia.2 Improved methods of immunologic marker evalua- 
tion have also increased the precision of diagnosis and classi- 
fication of the lymphoid malignancies, now permitting the 
detection of minimal residual di~ease.~,~  Most recently, the 
study of chromosomal abnormalities specific for the major 
immunologic subtypes of leukemia has pinpointed genes 
with pivotal roles in cell transformation: 
In this review, we summarize the key aspects of normal B- 
and T-cell ontogeny as it relates to the diagnosis and classifi- 
cation of acute lymphoblastic leukemia (ALL). We also ad- 
dress the critical issue of clinical relevance of immunologic 
marker evaluation in ALL and briefly compare the immu- 
nophenotypic findings between childhood and adult ALL. 
Because most of the differentiation antigens found on B or 
T lymphocytes  have also been identified on other cell types, 
we use the term lineage-associated, rather than lineage-spe- 
cific, throughout this article. 
DEVELOPMENT  OF  LYMPHOID CELLS 
Lymphocytes derive from pluripotent stem cells that also 
give rise to erythroid, megakaryocytic, and myeloid cells. 
Whether T and B lymphocytes originate from a common 
stem cell committed to the lymphoid developmental path- 
way is not known. Commitment to either the B-  or T-cell 
lineage occurs as progenitor cells enter the primary organs 
of  lymphocyte differentiation, ie, the bone marrow for B 
cells and the thymus for T cells. At the cellular level, the 
proliferation and differentiation of lymphoid progenitors is 
driven by the microenvironment  provided by these primary 
organs. In the bone marrow, this milieu, generally referred 
to as stroma, includes adventitial cells, reticular cells, endo- 
thelial cells, fibroblasts, macrophages, adipocytes, and an 
extracellular matrix. Stromal cells produce a variety of cyto- 
kines that are required for the differentiation and prolifera- 
tion of  B-lymphoid  cell^.^,^  In the thymus, a highly  spe- 
cialized  network  of  epithelial cells,  dendritic cells  and 
macrophages is essential for T-cell clonal expansion and 
selection. 
Generation of Immunologic Diversity 
The diverse repertoire of antigen specificities afforded by 
Igs and T-cell receptors for antigen (TCR) is generated by 
successive rearrangements of the genes encoding these pro- 
tein~.~.’  Diversity is enhanced by  random addition of nu- 
cleotides to the junctional regions of Ig loci in B cells or the 
TCR genes in T  When these rearrangements are 
productive (ie, result in an open reading frame for transcrip- 
tion of mRNA followed by translation to produce the pro- 
tein components of Ig or TCR), they promote further diver- 
sity through random association of different heavy and light 
Ig chains in B cells and different TCR chains in T  cell^.^^' An 
ordered sequence of gene rearrangement, shown in Figs  1 
and 2, has been postulated for normal B- and T-cell ontog- 
eny. Ig and TCR gene rearrangements have also served as 
clonal markers of leukemia, to the extent that specific pat- 
terns of rearrangement have been incorporated into some 
leukemia classification schemes?-I2 
Cell Markers 
Besides the proteins encoded by Ig and TCR genes, lym- 
phoid cells sequentially express an array of other lineage-re- 
lated cellular antigens during their normal maturation (Figs 
1 and 2). The list of lymphoid differentiation antigens and 
the MoAbs that recognize them has grown rapidly. Since 
1982, four international workshops have been held with the 
sole purpose of reaching a consensus on the nomenclature 
and specificity of these molecules. At the fourth workshop 
(Vienna, Austria, 1989), 35 new cluster of differentiation 
(CD) groups and subgroups were added, and seven previ- 
ously established groups were  redefined.13 Altogether, 89 
CD groups and subgroups (CDla to CD,78)  were desig- 
nated. Table 1 lists some of the properties and functions of 
the cellular differentiation antigens commonly recognized 
in immunologic marker studies of  the  acute leukemias. 
Only questions pertinent to the lymphoid-associated anti- 
gens will be addressed here; the reader is referred to a recent 
review for information on myeloid cells.14 
More than  20  differentiation antigens 
have been identified on B-lineage cells.” Their order of ex- 
pression during cell maturation has been the subject of in- 
tense study using panels of lineage-associated MoAbs. Evi- 
dently, CD  19 and cytoplasmic CD22 appear earliest during 
B-cell ontogeny and are expressed in virtually all cases of 
B-lineage  The  remainder  of  the  temporal  se- 
B-cell lineage. 
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Fig 1.  Hypothetical schema of marker expression  and gene rear- 
rangement during normal 8-cell ontogeny. 
quence can be summarized as CD24 +  CDlO +  CD20 + 
CD22 +  cytoplasmic Ig (clg) +  CD2  1 +  surface Ig (sIg) + 
CD23 (Fig 1).  According to the consensus hierarchy of Ig 
gene rearrangement during B-cell ontogeny, the assembly of 
Ig heavy-chain genes precedes the assembly of K light-chain 
genes, which in turn precedes that of X light-chain genes.18-20 
In contrast to heavy-chain gene rearrangements, light-chain 
gene rearrangements appear restricted to B cells, with only a 
few  exception^.^'-^^ 
Studies of antigen expression16,2"28  and Ig gene rearrange- 
in B-lineage ALL have led to different models of 
leukemic B-cell development. Nadler et alZ4  proposed dis- 
crete stages of neoplastic and normal B-lineage differentia- 
tion based on the expression of HLA-DR, CDIO, CD19, 
ment18-20 . 
T-cell Ontogeny 
and CD20 molecules.  greave^^'^^^ originally postulated that 
leukemic lymphoblasts are the neoplastic counterparts of 
normal  lymphopoietic  progenitors  "frozen"  at  various 
stages of development. Others15,16,26,3G32  subsequently docu- 
mented the existence of occasional lymphoid cells whose 
phenotypic  features  were  similar  to those  proposed  by 
Greaves. Leukemic clones lose their ability to differentiate 
but retain their proliferative p~tential.~~.~~  In this regard, the 
majority of B-lineage leukemic lymphoblasts have nonpro- 
ductive Ig gene rearrangements, consistent with their inabil- 
ity to develop n~rmally.'~ 
Borella and Sen33.34  first identified T lym- 
phoblasts by the ability of these cells to form rosettes with 
sheep erythrocytes (E-rosettes). Subsequent studies showed 
that heteroantisera  raised against thymocytes reacted not 
only with blasts from E-rosette-positive leukemias but also 
with those from other T-cell leukemia cases.35 Indeed, it has 
since been recognized that nearly one-half of T-cell cases do 
not form E-r~settes.~~,~'  In the past decade, the discovery of 
TCR genes3843  and the wider availability of MoAbs to T- 
cell-associated  antigens"  have  stimulated  remarkable 
progress in understanding the ontogeny of T lymphocytes. 
Similar to Ig genes, TCR genes rearrange during T-cell 
differentiation  to  permit  receptor  expression  and diver- 
~ity.~~  Two different types of TCR molecules  have been 
identified on T cells; both consist of a polymorphic hetero- 
dimer of two glycosylated polypeptide chains (a@  or 76) and 
a monomorphic glycoprotein  complex  (CD3). Extensive 
analysis of TCR expression during development has shown 
that, although TCR genes are frequently rearranged in B- 
lineage ALL, such changes are usually nonprodu~tive.~~~~~'~~ 
Traditionally, T cells have been classified according to 
changes in the expression of surface differentiation antigens 
(Fig 2). Reinherz et aP7  proposed a three-stage scheme of 
thymic maturation, which has provided a framework for the 
classification of T-cell ALL. However, there are exceptions 
to this model  for both normal thymocytes and leukemic 
cells, suggesting a continuum of phenotypic changes (rather 
T-cell lineage. 
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Fig 2.  Hypothetical schema of marker expression and 
gene rearrangement during normal T-cell ontogeny. 
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Table 1  . Commonly Recognized Leukocyte Differentiation Markers 
Cluster Designation  Molecular Mass (Kd)  Representative Antibodies/Function  Pattern of Reactivity 
B-lineage 
CD19 
CD20 
CD2 1 
CD22 
CD23 
CD24 
Cl9 
S4-l 
T-lineage 
CDla 
CD2 
CD3 
CD4 
CD5 
CD7 
CD8 
My  e  Io  i  d  - 
CD1 lb 
associated 
CD13 
CD14 
CD15 
CD33 
CD4 1 
CDw65 
Lineage- 
independent 
CD10 
CD34 
CD38 
CD45 
CD7 1 
gp95 
P35 
gp140 
9P135 
9P45 
9P42 
Depends on lg class 
Depends on lg class 
9P49 
gp50 
gp 16-26 
gp59 
gP67 
9P40 
9P32 
9Pl55 
gp150 
9P55 
Various 
9P67 
gp145/115 
Glycolipid 
84, Leul 2,  HD37/bridge for slg signal 
B1,  Leul 6/ion channel, protein kinase C 
substrate 
82, HB5/C3d receptor (CR2) and Epstein- 
Barr virus receptor, complex formation 
with slg and CD19 
Leul4, S-HCL1, HC39/related to neural cell 
adhesion molecule; bridge for slg signal 
Leu20, MHM6, Blast-2/low-affinity Fc 
receptor for IgE 
BA-1, VIB-EB/not determined 
Conventional antisera and MoAbs 
Conventional antisera and MoAbs 
T6,  NAl/34. LeuG/MHC-like protein; can 
associate with p2 microglobulin 
T1  1 ,  Leu 5b/E-rosette receptor, ligand for 
leukocyte function antigen 3 
T3,  Leu4, UCHT1  /signal transduction from 
T-cell receptor to cytoplasm 
T4,  LeuBa/involved in MHC class II- 
restricted antigen recognition, HIV 
receptor 
T1, Leul, UCHT2/T-cell proliferation 
T16, Leu9, 3Al/Fc receptor for IgM 
T8,  LeuPa,  UCHT4/involved in MHC class 
I-restricted antigen recognition 
Mol, Leul5/adhesive molecule, C3bi 
My7. MCS2/aminopeptidase  N 
My4, LeuM3, Mo2, VIM1  3/phosphatidyl- 
inositol glycan-linked protein 
My1  ,  MCS1, VIM-D5/X-Hapten,  3 fucosyl- 
N-acetyl-lactosamine 
My9. LeuM9/not determined 
receptor 
J15, HPLl ,  PL273/platelet glycoprotein Ilb/ 
VIM2, VIM8/ceramide dodecasaccharide 40 
llla complex 
J5, BA-3, VILAl/neutral endopeptidase 
MylO, BI-3C5, ICH3/not determined 
OKTl 0, Leul 7/not determined 
T200, T29/33, HLe-1 /not determined 
T9, VIP1 /transferrin receDtor 
Precursor B cells, B cells 
Subpopulation  of precursor B cells, all B cells 
Subpopulation  of B cells 
Precursor B cells. B cells 
Subpopulation  of B cells 
Subpopulations of precursor B  cells, 
Pre-B cells 
B cells 
granulocytes 
Cortical thymocytes, Langerhans cells, 
T cells, most natural killer cells 
subpopulation of B  cells 
Mature T cells 
Subpopulation of cortical thymocytes, helper/ 
inducer T cells, subpopulation of monocytes 
and macrophages 
Thymocytes, mature T lymphocytes, 
subpopulations of B cells 
Almost all T cells, natural killer cells, 
subpopulation of immature myeloid cells 
Subpopulation of cortical thymocyte, cytotoxic/ 
suppressor T cells, subpopulation  of natural 
killer cells 
Monocyte, macrophages, granulocytes, natural 
Almost all myeloid cells 
Monocytes, macrophages 
killer cells 
Granulocytic lineage, monocytes (weak 
Majority of myeloid and monocytic cells (except 
Megakaryocytes, platelets 
expression) 
for granulocyte) 
Myeloid and monocytic cells and some of their 
precursors 
Subpopulations of B and precursor B cells, 
subpopulation of cortical thymocytes, 
granulocytes 
Precursors of lymphoid and myeloid cells 
Activated T and B cells, precursor cells, 
subpopulation of B cells, plasma cells 
All leukocytes 
Proliferatincl cells, activated cells, macroDhaaes 
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than discrete stages)  during the developmental process.58  Of 
the various modifications of the Reinherz model used to 
subclassify T cells, we prefer the one based largely on expres- 
sion of CDl and CD3.59360  Thus, cases considered to have 
the early thymocyte phenotype (stage I) express CD7, CD2, 
and CD5 without CD1, CD4, CD8, and CD3. Those with 
an intermediate phenotype (stage 11) are characterized by 
expression of CD7, CD5, CDI, and CD2 with variable ex- 
pression of CD4 and CD8; CD3 may be weakly expressed in 
some cases. In many cases, the malignant cells express both 
CD4 and CD8. In the mature thymocyte subgroup (stage 
III), cells express CD3, CD5, CD7, and CD2. CD4 and CD8 
are also present in most of these cases but generally appear 
singly rather than in combination. 
Campana et a1,6’ using five MoAbs, recently investigated 
TCR protein expression in the acute leukemias. These re- 
agents reacted exclusively with CD3+ T cells and did not 
label B-lineage or myeloid blast cells. These investigators 
proposed a new system for the classification of T-cell ALL 
based on the type and pattern of TCR protein expression 
(membrane or cytoplasm). 
Lineage-independent  markers.  Several CD antigens not 
related to a specific cell lineage are routinely measured on 
leukemic cells (Table 1).  CDlO, the common ALL antigen, 
was among the first differentiation  antigens used to subclas- 
sify acute lymphoid leukemia. Initially described in  1975 
(Greaves et a162),  this 100-Kd glycoprotein was later identi- 
fied as the membrane-associated  enzyme neutral endopep 
tida~e,~~,~~  which cleaves peptides at the amino terminus of 
hydrophobic re~idues.~~.~~  Its presence on leukemic  cells was 
originally taken as a marker of common ALL,67-69  whereas 
its absence in 5% to 15% of non-T, non-B cases was used to 
recognize ALL variously termed null cell, unclassified, or 
~ndifferentiated.~~~~  More recent studies have shown CD  10 
expression on leukemic cells of both the T and B lineages 
and on some nonhemopoietic cells as we11.68,75-77  The role of 
the antigen in leukemic cell proliferation  and differentiation 
remains uncertain. 
The CD34 antigen, a molecule of  115 Kd  mass, is ex- 
pressed selectively by primitive myeloid and lymphoid pro- 
genitor ~ells.~~-~~  The 28-kb gene encoding this protein was 
recently cloned and its genomic DNA sequence was charac- 
terized,81.82  but the function of the product has not been 
defined. In a Pediatric Oncology Group study of 795 chil- 
dren with  non-T, non-B ALL,  CD34 expression was de- 
tected in 74% of the cases.83  CD34+ blast cells were more 
likely to coexpress  CD22, CD9, and CD13 antigens, but less 
likely to coexpress cIg. From a study of a limited number of 
cases,  CD34 antigen  expression was  suggested to  occur 
more often in non-T, non-B ALL than in T-cell 
CD45, the leukocyte common antigen, is found on all 
hematopoietic cells except erythrocytes  and platelets, and is 
absent from nonhematopoietic tissues.86  CD45 antigens be- 
long to a family of cell surface glycoproteins with a heavily 
glycosylated  extracellular domain, a transmembrane seg- 
ment, and a large cytoplasmic domain that has tyrosine 
phosphatase a~tivity.~~,~~  The CD45 molecule appears in at 
least four discrete forms that differ in their carbohydrate 
and protein backbone  structure^.^^*^^ Several studies suggest 
that CD45 may be involved in the regulation of hematopoi- 
etic  cell  growth,  differentiation, and cell  activati~n.~~*~~ 
Despite the ubiquitous expression of this antigen on normal 
leukocytes and their precursors,  it  may  be  absent from 
some cases of acute leukemia or from some leukemic cell 
In our recent study of 249 childhood ALL cases, 
CD45 expression was undetectable or vanishingly low on 
lymphoblasts from 32 patients (1  3%), all of whom had B- 
lineage ALL.93  The percentage of blast cells expressing this 
antigen was higher in T-cell than in B-lineage cases. There 
appeared to be an inverse relationship between CD45 ex- 
pression and that of the CD20 and CD34 antigens. This 
finding paralleled the association seen during normal B-cell 
development, except for an increase in  CD20 positivity 
while CD45 expression declined.9s95 
CD38 (the plasma cell activation antigen) and CD7 1 (the 
T-cell activation antigen) are integral membrane glycopro- 
teins appearing at the earliest stages of thymocyte matura- 
ti~n.~~.~~‘~  CD38 is expressed by about 20% of normal bone 
marrow cells, mitogen-activated peripheral T lymphocytes 
and plasmacytes, and blast cells of the acute lymphoid and 
myeloid leukemias, but is absent on virtually all resting T 
 lymphocyte^.^^.^^.^^ Despite its wide expression, the precise 
function of CD38 is not known. Among CD34’  human 
progenitor cells, the expression of CD38 has been correlated 
with lineage commitment (CD38- cells are not committed 
to a particular lineage and are capable of extensive self-re- 
newal).”’  Recently, from observations of HLA-DR expres- 
sion,  Huang  and  Terstappenlo2 further  subdivided the 
CD34’  CD38-  pluripotent  stem cells  from human fetal 
bone marrow into two distinct subsets. The HLA-DR+ sub- 
set can differentiate into cells of all hematopoietic lineages 
and the  HLA-DR-  subset into hematopoietic precursors 
and stromal cells capable of supporting their differentiation. 
CD7 1 is generally expressed more strongly by proliferating 
or transformed cells than by resting cells because of its role 
in iron ~ptake.~~,~~  The antigen has been detected on divid- 
ing cells of all hematopoietic lines and on malignant lym- 
phoid and myeloid cells.57.97,98  In a recent  study by  our 
group, all 62 T-cell ALL cases and 238 of  263 B-lineage 
ALL cases expressed CD38.1°3  CD38 expression did not cor- 
relate with the presence of the B-lineage differentiation  anti- 
gens CD19, CD20, CD21, and CD10. Likewise, CD71 ex- 
pression was found more often in T-cell cases (92%)  than in 
B-lineage cases (32%),  and there was no correlation between 
CD7 1 expression and the expression of B-lineage differen- 
tiation antigens or the percentage of cells in S-phase.Io3 
CLASSIFICATION  OF  CHILDHOOD ALL 
Differences in the expression of surface membrane anti- 
gens or cytoplasmic components are used to identify and 
classify lymphoproliferative diseases by  cell of origin and 
stage of differentiation.2  Studies indicate that the expression 
of cytoplasmic CD3 or CD22 is specific for the T- and B-cell 
lineages, respe~tively.~~~’”~~~~  However, virtually all known 
cell surface “differentiation”   antigen^,'^^,'^^ as well as Ig and 
TCR  gene  lack  lineage specificity; 
even the cytoplasmic expression of CD3 has been reported 
in acute myeloid leukemia.”’ We recommend that the clas- 
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sification of leukemia be based on the cellular pattern of 
reactivity to a panel of lineage-associated MoAbs. By  this 
method, childhood ALL can be broadly classified as having 
a T-lineage (cytoplasmic  CD3+, CD7+ plus CD5+ or CD2+, 
or both) or B-lineage (CDI9+, CD22+) origin. The latter 
classification includes three major subtypes: B (expression 
of sIg heavy and light chains), pre-B (cIg'),  and early pre-B 
(cIg-,   SI^-)."^^"' Transitional pre-B ALL (cIg+,  sIgp+ and 
sIg K-,  X-)  is a recently recognized 
IMMUNOPHENOTYPIC  AND  GENETIC  CORRELATIONS 
More than 90%  of childhood ALL cases have clonal chro- 
mosomal rearrangements? Karyotypic abnormalities are 
more commonly detected in B-lineage leukemia; only about 
three-fourths of T-cell cases have such  finding^."^."' The 
modal chromosome number (ploidy) of leukemic cells var- 
ies by immunophenotype (Table 2).""'"  The frequency of 
hyperdiploidy >50  chromosomes, a favorable prognostic 
feature, is highest  in  cases  of  CDIO+ early pre-B ALL, 
whereas pseudodiploidy is present in the majority of pa- 
tients with CD  10-  early pre-B ALL and in virtually all cases 
of B-cell  ALL.  Cases  of  pre-B ALL  are less likely  than 
CDIO'  early pre-B ALL to be hyperdiploid >50.  T-cell ALL 
is characterized by a high frequency of pseudodiploidy; hy- 
perdiploidy >50 is rare. 
An increasing number of structural chromosomal abnor- 
malities have  been  recognized  as  nonrandom  changes, 
many ofwhich are associated with a specific immunopheno- 
type (Table 3),4,'18 suggesting a relationship to leukemogen- 
esis.  Translocations, most  often involving reciprocal ex- 
changes  of  DNA,  are  the  most  prominent  of  these 
alterations, occumng  in  up to  50% of  childhood ALL 
 case^.^*'^^ Molecular analyses of breakpoint regions in leu- 
kemic lymphoblasts  have identified many genes whose pro- 
tein products appear to play important roles in malignant 
transformation and proliferation; some of the more com- 
mon findings are listed in Table 3. Continued study ofthese 
gene rearrangements, and their biologic effects in leukemic 
cells, will be  critical to our understanding of specific im- 
munophenotypes and perhaps to the formulation of new 
treatment strategies. 
Chromosomal translocations affect TCR genes in approx- 
imately one-half of T-cell ALL casesm and involve Ig genes 
in virtually all B-cell ALL   case^,"^,'^^ suggesting that  Ig/ 
TCR recombinase and class-switch enzymes are mediators 
of interchromosomal translocation in these cases.'"  B-cell 
ALL is invariably associated with one of three specific chro- 
mosomal translocatibns: the t(8; 14)(q24;q32.3)  in approxi- 
mately  80%  of  cases  and  the  t(2;8)(p1  I-p12;q24)  or 
t(8;22)(q24;q  I 1) in the remainder.1'g.'20  These rearrange- 
ments consistently bring the MYC proto-oncogene on chro- 
mosome 8(q24) near the transcriptionally active gene for 
the Ig heavy chain on 14q32, the K light chain on 2plI-pl2, 
or the X light chain on 22q I 1  leading to aberrant activa- 
tion of MYC.'22-'24 
There  is  no  apparent  relationship between  particular 
translocations in T-cell ALL and the level  of thymocyte 
maturation.60  However, it is interesting that normal karyo- 
types are found more often in T lymphoblasts in early stages 
of development.60  Among childhood T-cell ALL cases, the 
t(l1;14)(p13;ql I) is the most common nonrandom abnor- 
mality, occumng in 7% of  patient^.'^' In virtually all cases 
with a t(  1 1; 14), the blast cells coexpress CD4 and CD8 anti- 
gen~.'~'  The t( 1;14)(p32-p34;ql  I) has been recognized in 
3% of T-cell ALL cases.i26  As a result of this rearrangement, 
the TALI gene (also known as TCLS or SCL) is markedly 
overe~pressed.'~~~'~~  Recent studies indicate that the gene 
can also be activated by  interstitial deletions on chromo- 
some I without cytogenetic abnormalitie~.'~~-'~'  In fact, the 
TALI/SCL gene, a member of the helix-loop-helix family 
of transcription factors, is probably the most commonly in- 
volved proto-oncogene in T-cell ALL, affecting up to 25% 
of pediatric  case^.'^^,'^' 
Approximately 25% of cases of pre-B ALL have a specific 
chromosomal translocation, t( 1; 19)(q23;p  1 3).'32-'34  Over- 
all, the t(  1 ;  19)  is found in 5%  to 6% of childhood ALL cases, 
making it the most common chromosomal translocation in 
this di~ease.~  The translocation breakpoint on chromosome 
19 occurs within a single intron of the E2A gene, which 
encodes a transcriptional factor containing a helix-loop-he- 
lix DNA binding motif and dimerization d~main.'~'-'~'  The 
breakpoint on chromosome  lq23 interrupts a homeobox 
gene known as PBX1.'36*'37  As a result, chimeric transcripts 
with oncogenic potential are formed that fuse coding se- 
quences of the E2A gene in frame with the PBXI sequences. 
Although approximately I % of early pre-B cases also have a 
t(  1 ;  19)-cytogenetically  indistinguishable from that found 
in pre-B ALL"83'38-'40-they have different clinical and mo- 
lecular  These cases are associated  with hyper- 
dipoloidy >50 and lack of E2A-PBXI fusion protein, and 
have a favorable prognosis. 
The  Philadelphia  chromosome  [22q-  chromosomal 
Table 2.  Percent Distribution of Ploidy Subgroups in Childhood ALL by Immunophenotype 
Early Pre-B 
Transitional 
Subgroup  CD 10'  CD10-  Pre-B  Pre-B'  B  T 
Hypodiploid  9  2  13  7  0  3 
Pseudodiploid  32  71  52  15  98  63 
Hyperdiploid  47-50  19  13  16  7  2  2 
Hyperdiploid  250  33  2  15  21  0  2 
Near-tetraploid  <l  2  Cl  0  0  2 
Normal  6  10  3  50  0  28 
Data from Pui and Crist"'  with modifications. 
Results based on limited number of cases. 
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Table 3.  Nonrandom  Chromosomal Translocations  Commonly Associated With Specific lmmunophenotypes  of Childhood ALL 
lmmunophenotype 
and Translocation 
Frequency 
I%  of total cases)  Involved  Genes'  Protein Product 
Pre-B cell/early pre-8 cell/T-cell 
Pre-B cell/early pre-B cell 
t(9;22)(q34;qll) 
t(l;19)(q23;pl3) 
t(4;l l)(q21;q23) 
dic(9;  1  2)(p  1  1  -p 1  2; p 1  2) 
t(  1 1  ;19)(q23;pl3) 
t(17;19)(q22;p13) 
t(l1;14)~13;qll) 
t(5;14)(q3 1  ;q32) 
t(9;11)(~21-~22;q23) 
T-cell 
t(l1;14)(p15;qil) 
t(  10; 14)(q24;qll) 
t(  1  ;14)(p32-p34;ql  1) 
t(7;9)(q34;q32) 
t(7;9)(q34;q34.3) 
t(1;7)(p34;q34) 
t(8; 14)(q24;q32.3) 
t(8;22)(q24;qll) 
t(8;14)(q24;ql  1) 
t(7;19)(q35;p13) 
B-cell 
t(2;8)(~11-~12;q24) 
3-5 
5-6 
2 
1 
<1 
<1 
<l 
<1 
1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
1-2 
<1 
<1 
ABL 
PBXI 
AF-4 
Unknown 
lL3 
ALL IIMLL 
AF-9 
HLF 
TTGZIRHOMZ 
TTG IIRHOM  1 
TCL IIHOX  I  1 
TCLMTAL  IISCL 
MYC 
TCRP 
TCRP 
TCRP 
LCK 
MYC 
MYC 
IGK 
BCR 
E2A 
ALL IIMLL 
Unknown 
ENL 
ALL IIMLL 
EZA 
ISH 
TCRd 
TCR6 
TCR6 
TCR6 
TCRa6 
TAL2 
TAN  I 
LYL I 
TCRP 
IGH 
ISL 
MYC 
E2A-PBX1 fusion protein 
ALL1  -AF-4 fusion protein 
Interleukin-3 
ALL1  -ENL fusion protein 
ALL1  -AF-9 fusion protein 
E2A-HLF fusion protein 
Zinc-finger protein (rhombotin 2) 
Zinc-finger protein (rhombotin 1) 
Homeodomain protein 
Helix-loop-helix protein 
Helix-loop-helix zipper protein 
Helix-loop-helix protein 
Helix-loop-helix protein 
Tyrosine kinase 
Helix-loop-helix zipper protein 
Helix-loop-helix zipper protein 
Helix-loop-helix zipper protein 
Abbreviations:  ABL, cellular homologue  of the Abelson murine leukemia virus oncogene; BCR, gene containing  the breakpoint  cluster region  involved 
in Ph translocation; PBXI, pre-B-cell  transforming gene; E2A. gene for lg enhancer binding proteins El  2/E47; AF-4, AL- I  fused gene from chromo- 
some 4; ALL, acute lymphoblastic  leukemia gene; MLL, myeloid/lymphoid, or mixed-lineage, leukemia gene; lL3, interleukin-3  gene; ENL, eleven-nine- 
teen leukemia; AF-9, ALL fused gene from chromosome 9;  HLF, hepatic leukemia factor gene;  TCR, T-cell receptor gene;  TCL, T-cell leukemia/lym- 
phoma breakpoint  regions; TTG, T-cell translocation  gene; RHOM, rhombotin gene; HOX  homeobox gene; IGH, lg heavy-chain gene;  TAL, T-cell acute 
leukemia gene;  TAN, translocation-associated  notch homologue; MYC, cellular homologue of the transforming sequence of the avian myelocytomato- 
sis virus; LYL, lymphoid leukemia gene; LCK, lymphocyte-specific protein tyrosine kinase; IGK. lg K light-chain  gene; IGL, lg h light-chain  gene. 
The order of genes (from left to right) corresponds  to the order of chromosomal breakpoints in the first column. 
marker resulting from the t(9;22)]  and the t(4;l I) are found 
in  3% to  5%'41s'42  and 2% of  childhood ALL 
respectively. The t(9;22) fuses part of the ab1 gene on chro- 
mosome 9 with the bcr gene on chromosome 22; the result- 
ing chimeric protein shows increased tyrosine kinase activ- 
ity  and is  believed  to  play  a  major  role  in  malignant 
transformati~n.'~~  The  t(4;  1  I) cleaves the  ALL-I  gene 
within the coding region, resulting in fusion of the open 
reading frames of ALL-I with the AF-4 gene on chromo- 
some 4 in pha~e.'~~,'~~  ALL-I encodes a putative transcrip- 
tion factor, whereas the function of the AF-4 protein is un- 
clear. Both translocations are associated with an extremely 
poor prognosis. Although most of the Philadelphia  chromo- 
some-positive cases have an early pre-B  (75%) or pre-B 
(16%)  phenotype, T cells are involved in 9% of the cases.142 
Almost all cases of the t(4;Il) are classified as CDIO- early 
pre-B  or  pre-B  ALL.'43,'"  Interestingly,  cases  with  the 
t(9;22) or t(4;l I),  in addition to those with  14q32 trans- 
locations,  frequently  express  myeloid-associated  anti- 
gens.4,107,143,148 
IMMUNOPHENOTYPIC  AND  CLINICAL CORRELATIONS 
The distribution of specific immunophenotypes of ALL 
is clearly influenced by age. In infants, there is a preponder- 
ance of CD  IO-  early pre-B ALL and a lack of T-cell ALL 
(Table 4).L49-'53  In fact, the frequency of CDlO expression 
decreases with  younger age among infants. In one study, 
CDlO expression was found in only  1 of  10 infants with 
early pre-B ALL who were less than 6 months of age, in 2 of 
I1  between 6 to 12 months of age, and in 16 of 18 between 
12 to 18 months of age.149  Likewise, the proportion ofpre-B 
cases with CDlO expression was lower in younger infants. 
Similar  findings  have  been  reported  by  several  other 
Table 4.  Percent Distribution of ALL lmmunophenotypes 
Among Different Age Groups 
~~  ~  ~~  ~ 
Infants  Children  Adolescents  Adults' 
(<l  5yr.  (1 5tolOyr.  (>10yr,  (>15yr. 
lmmunophenotype  n = 70)  n = 1,006)  n = 225)  n = 1,145) 
Early pre-B  64  68  58  51 
-  CD 1  O+  49  94  87 
CD10-  51  6  13  - 
Pre-B  26  18  18  Unknown 
T  6  13  23  22 
B  4  1  1  4 
Modified and reprinted with permission  from Crist et al.154 
The values are weighted means from eight different studies. 
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groups.15@152  Myeloid-associated  antigens  (CD  15  and 
CDw65) are preferentially  expressed in infant cases with the 
t(4;l l).143,151  T-cell  ALL  occurs  in  approximately  one- 
fourth of adolescent cases, a much higher frequency than 
that in younger children and infants.15G156  lmmunopheno- 
typic subtypes of ALL also differ according to geographical 
and ethnic settings. Black African children have a signifi- 
cantly lower  incidence of  CD10'  B-lineage  ALL  and a 
higher proportion of T-cell ALL.L57  The low incidence of 
ALL and the lack of an apparent age peak at 2 to 5 years in 
black African children are largely accounted for by this defi- 
cit of CD 10'  B-lineage ALL cases. It has been postulated 
that an improved socioeconomic  situation and hygiene with 
altered patterns of infection in infancy results in increased 
risk of CDlO+ B-lineage ALL in developed countries.157 
T-cell ALL 
Approximately 15%  of cases of childhood ALL are classi- 
fied as T-cell  Male gender, older age, higher 
leukocyte counts, the presence of a mediastinal mass, and 
central nervous system (CNS) leukemia are typical features 
of this form of the disease (Table 5).67"9,76,158,159,161 
Children with T-cell ALL generally have a poorer progno- 
sis than do those with early pre-B or pre-B ALL,6749,76*15s'62 
although in one clinical trial of intensified chemotherapy 
including high-dose asparaginase and an anthracycline,  the 
T-cell phenotype failed to show prognostic ~ignificance'~~ 
(Table 6). In a recently completed St Jude study, the 5-year 
event-free survival estimate (*SE)  was 7 1% f  4% for all 358 
patients, but was only 5 1  % k 1 1  % for the 62 T-cell patients 
(Fig 3).'64 However, many of the failures were due to re- 
lapses in the CNS, most of which were successfully treated 
(C.-H. Pui, unpublished data). 
Numerous attempts to identify subsets of  T-cell cases 
with  prognostic relevance  have  yielded  inconsistent re- 
sult~.~~,~~-~~,~~,~~-~~,~~~,~~~,~~~  Presenting features that we  have 
found to be associated with an adverse prognosis in T-cell 
ALL include older age group (2  15 years), French-Ameri- 
can-British (FAB) L2 morphology, abnormal leukemic cell 
karyotype, late thymocyte stage of differentiation (surface 
membrane CD3 expression), and  lack  of  CDlO expres- 
In a multivariate analysis, abnormal karyotype 
and lack of CD 10 expression were independently associated 
with a poorer clinical outcome.77 
Table 5.  Frequency (%) of Presenting Features Among 1476 Consecutive Childhood ALL Cases According to Immunologic Subclass 
Early Pre-B  Pre-B  Transitional  B-Cell  T-cell 
Feature  (n = 995)  (n = 285)  Pie-B (n = 20)  (n = 17)  (n = 216) 
Male  54  52  41  67  68 
Race 
White  80  73  70  78  70 
Black  9  13  5  11  19 
Hispanic  7  11  5  11  5 
Other  4  3  20  0  6 
<1.5  6  9  0  17  2 
1.5-7  66  61  70  47  45 
8-9  13  15  25  12  26 
210  15  15  5  24  27 
<10  50  42  50  30  20 
10-49  35  33  45  38  29 
50-99  8  12  5  19  13 
2100  7  13  0  13  38 
t20  21  23  25  38  13 
20-99  53  48  60  62  44 
2100  26  29  15  0  43 
t7.5  50  44  58  50  27 
7.5-9  32  28  21  12  22 
210  18  28  21  38  51 
Marked hepatomegaly"  7  8  10  19  13 
Age (~r) 
Leukocyte count (X  1  09/L) 
Platelet count (XI  09/L) 
Hemoglobin level (g/dL) 
Marked splenomegaly*  9  11  15  13  21 
Marked lymphadenopathy  3  3  -  24  20 
Mediastinal mass  1  1  0  0  52 
CNS leukemia  4  5  0  18  5 
PAS positivity  65  60  -  19  35 
CD 10 positivity  90  91  100  50  30 
HLA-DR positivity  98  97  100  94  17 
Chromosomal translocation  45  64  43  100  49 
Data from Crist et al."" 
Palpable below umbilicus. 
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Table 6.  Relation of lmmunophenotype to Clinical Outcome in 
Children With ALL Treated on Contemporary Protocols 
~~  ~ 
No.  of  Estimated Event-Free 
Subgroup  Patients  Survival (+SE)  Source of Data 
Early pre-B  186 
679 
Pre-B  82 
285 
Transitional pre-B  17 
E-cell  51 
20 
11 
41 
T-cell  62 
363 
39 
80 
My+ ALL  50 
53 
79% + 5%  at 5 yr 
~70%  at 3 yr 
71% + 9%  at 5 yr 
-70%  at 3 yr 
93% ? 17%  at 4 yr 
-60%  at 4 yr 
65%  5%  at 1.5  yr 
64%  (31-89%) at 1 yr 
78% f  6%  at 5 yr 
51%+ ll%at5yr 
~50%  at  4 yr 
77%  i= 7%  at 4 yr 
56%  i= 6%  at 4 yr 
85%  ? 6%  at 3 yr 
30%  ? 13%  at 3 yr 
Pui et allM 
Crist et all3' 
Pui et aP4 
Crist et aP2 
Koehler et 
Crist et 
Patte et 
Hann et all7' 
Reiter et all7' 
Pui et aP4 
Crist et a116* 
Clavell et 
Ludwig et allm 
Pui et aizo3 
Wiersma et atzoo 
Limited to studies in the 1980s. 
The biologic basis for the adverse treatment outcome in 
CDlO- T-cell cases is unknown. CDlO+ and CD10- sub- 
groups lack major differences in clinical or cytogenetic fea- 
tures, except that CDlO'  cases are more likely to have 9p 
abnormalities and less likely to have CNS leukemia.77  How- 
ever, the different patterns of cell surface antigen expression 
between CDlO+ and CD10- cases suggest biologically dis- 
tinct species of T-cell ALL. Compared with CDlO- T-cell 
cases, the CD  1  Of cases have a high frequency of CD  1, CD4, 
and CD8 antigen expression, but a lower frequency of CD3 
expression. Perhaps of greater interest is the finding of a 
high percentage of CDlO+ T-cell cases (78%)  with expres- 
sion of CD21,77  an antigen that serves as the receptor for 
C3d complement component and Epstein-Barr virus, and is 
expressed late in B-cell  ont~geny.'~,''  Finally, in a recent 
study, we showed that expression of CD7 1, a T-cell activa- 
tion  antigen,  has  no  prognostic  significance  in  T-cell 
ALL  IO3 
B-Cell ALL 
B-cell  ALL accounts for approximately 2% of  cases of 
childhood ALL and is usually characterized by FAB L3 cel- 
lular morphology, male sex, white race, older age at diagno- 
sis, and extramedullary disease (eg, lymphomatous masses, 
CNS di~ease).'~~,'~'  More than 90% of cases express cell sur- 
face Ig  p heavy chains. Of these, approximately two-thirds 
coexpress  K  light chains and one-third X light chains on the 
cell surface.'67  Once given an extremely poor progn~sis,~.'~' 
patients with B-cell ALL now have a reasonable expectation 
of long-term survival. Cure rates of 60% to 78% have been 
achieved in contemporary treatment programs that feature 
short periods of fractionated high-dose cyclophosphamide, 
high-dose cytarabine and methotrexate, and intensive intra- 
thecal chemotherapy (Fig 3 and Table 6).I7&l7'  However, 
patients with CNS involvement or massive tumor burdens 
continue to fare p~orly.'~~~'~~,'~' 
Pre-B ALL 
The pre-B immunophenotype  accounts for about one- 
fourth of cases of newly diagnosed childhood ALL.'i4~L32~L7~i75 
Leukemic cells from most patients with pre-B ALL express 
HLA-DR (98%)  and the CDlO antigen (94%).'76  Compared 
with findings in early pre-B ALL, pre-B leukemia develops 
more often in blacks; has a larger leukemic cell burden, as 
reflected by higher leukocyte counts and serum lactic dehy- 
drogenase levels;  has higher  hemoglobin levels;  and has 
lower periodic acid-Schiff (PAS)   score^.'^^*'^^ Pre-B lympho- 
blasts are also more likely to have a DNA index of less than 
1.16, a pseudodiploid karyotype, and chromosomal translo- 
cations, and is less likely to be hyperdiploid >50.'32*'76  Re- 
cent studies have shown that the high-risk features formerly 
ascribed to pre-B ALL in general are closely associated with 
the presence of the t( 1 ;  1  9).'38,139 
Earlier trials conducted by the Pediatric Oncology Group 
(POG) indicated that children with pre-B ALL fare worse 
than those with early pre-B ALL.'75,'76  In a subsequent POG 
trial (ALinC 14) of antimetabolite-based intensive chemo- 
therapy, pre-B cases without the t( 1 ;  19) had outcomes simi- 
lar to results for early pre-B ALL, whereas t( 1;19)-positive 
pre-B cases fared worse (Table 6).'39  An unfavorable prog- 
nosis for pre-B cases with the t( 1;19) was also noted in St 
Jude Total Therapy Study X, although in Study XI, which 
tested a much more intensive regimen, patients with the 
t(1;19) had essentially the same outcome as those without 
this rearrangement (Table 6).'38  In a recent update of these 
results, the estimated 5-year event-free survival (+SE) for 
the t(1;19) cases was 80% f  21%.'@  Although this finding 
should be  viewed  as preliminary owing to the relatively 
small number of cases studied, it supports the contention 
that effective therapy can override the influence of adverse 
biologic risk  factors. A recent study of the clinical signifi- 
cance of two forms of the t( 1 ;  19) in pre-B ALL suggested 
that the balanced form was associated with a poorer progno- 
sis than the unbalanced translocation [der( 19)t(  1 ;  1  9)],'77  a 
finding that requires confirmation. 
Early Pre-B ALL 
Most cases of ALL (~60%)  involve  the early pre-B pheno- 
type. HLA-DR and CD19 antigens are present on lympho- 
100 
Early Pre-0 
Pre-B 
79(5)% 
n=  166 
71(6)% 
".. 
T-cell  51( 11)%  I 
a'  201 
-01234567 
Years From Diagnosis 
Fig 3.  Event-free survival by immunophenotype  in 340  consecu- 
tively  treated  patients  (St. Jude  Children's  Research  Hospital, 
1984-1  988). Numbers on the curves are 5-year results with stan- 
dard errors of the mean (SE). Therapy was not specifically targeted 
by  immunophenotype in this series, with the exception of  B-cell 
ALL. 
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blasts in virtually all of these cases. Although, collectively, 
early pre-B cases are more likely to have favorable present- 
ing features (eg, age range of 1 to 9 years and low leukocyte 
COU~~S),~,~~,~~,~~,~~~,~~~  they constitute a variety of subgroups 
with diverse clinical and biologic features and outcome. 
Many  higher-risk  features within  the early pre-B sub- 
group (eg,  hyperleukocytosis,  leukemic  cell  DNA index 
<  1.16, or pseudodiploidy) are related to the absence of the 
CD  10 marker, a feature common to infants.67-70274  In at least 
two st~dies,~~,~~  CD  10 expression lost its prognostic impact 
when infants were excluded from analysis. Thus, the poor 
prognosis of CD  IO-  B-lineage ALL appears confined to in- 
fant cases. 
The clinical relevance of CD34 expression was recently 
assessed in a POG  This marker was detected more 
often in early pre-B than in pre-B cases (79%  v 6 1  %),  and its 
presence was associated with hyperdiploidy >50, a lower 
frequency of initial CNS leukemia, and a favorable progno- 
sis. We have recently confirmed the relationship between 
this marker and favorable presenting features and outcome 
in B-lineage ALL.'78  CD24 is acquired during early develop- 
mental stage of  B-cell ontogeny. The lack of this antigen 
expression in leukemic  cells corresponds to a very early 
stage  of  B-lineage  ALL.I5 Interestingly,  a  recent  study 
showed that the lack of CD24 expression was associated 
with intrinsic radiation resistance at the level of primary 
clonogenic b1a~ts.I~~ 
Three additional antigens-CD45,  CD38, and CD7  1- 
do not appear to convey clinically useful information  in 
cases of early pre-B ALL.93,Lo3  CD45 was expressed in 84% 
of early pre-B and 8  1  ?h of pre-B cases. Cases lacking CD45 
had significantly lower leukocyte counts and lower serum 
lactic dehydrogenase levels and were more likely to have 
leukemic cell hyperdiploidy >50 or a DNA index 2  1.1 693- 
all favorable presenting features in this  Interest- 
ingly, there was an inverse linear correlation between CD45 
expression and the DNA index, suggesting that the cellular 
cytoskeletal proteins that anchor the CD45 antigen'"  are 
related to orderly cell mitosis. However, although clinical 
outcome clearly worsened as the level of CD45 expression 
increased in these cases, the prognostic impact lessened sub- 
stantially after adjustment  for DNA index. Similarly, the 
activation antigens CD38 and CD7  1 lacked prognostic sig- 
nificance in a recent study.103 
Transitional Pre-B ALL 
A small subset of children ( N  I %) with ALL was recently 
found to have blasts that express cytoplasmic and surface p 
heavy chains but not Ig light chains, indicating that these 
cells are in transition between the pre-B and B stages of 
differentiati~n."~  These cases were termed transitional pre- 
B ALL because their blasts lacked the cytoplasmic or sur- 
face light chains that typically characterize normal B cells. 
They also lacked FAB L3 morphology or the chromosomal 
translocations associated with B-cell ALL, and had lower 
leukocyte counts as well  as a higher prevalence of DNA 
indexes 2 1.16 than did cases of pre-B ALL. Identification of 
patients with transitional pre-B ALL is important because, 
unlike patients with B-cell ALL, they have an excellent clin- 
ical outcome when treated with antimetabolite-based che- 
motherapy. Transitional pre-B cells have also been identi- 
fied  at  low  frequency  in  normal  bone  marro~,~~~-'~~ 
indicating that surface marker expression of heavy chains 
does not require light chain production. 
MIXED-LINEAGE ANTIGEN  EXPRESSION 
Since the early 198Os, it has been recognized that leuke- 
mic blast cells can coexpress antigens associated with more 
than one lineage.'06.'07.'4s*'8"207  This lineage heterogeneity 
has been variously explained as a reflection of aberrant gene 
expression, malignant transformation  of pluripotent  pro- 
genitor  cells, or immortalization  of  rare progenitor  cells 
coexpressing features of more than one lineage.106.'84  Nu- 
merous terms have been used to describe these cases, but 
standard nomenclature is la~king.'~~~'~~  Recently, rare sub- 
populations  of  normal  marrow  B-lymphoid  cells  were 
found  to  express  "asynchronous"  immunophenotypes 
characteristic of some B-lineage ALL cases3' Moreover, the 
CD2 molecule was also found on normal human B-lym- 
phoid progenitors.208  Together, these findings suggest that 
some progenitor cells may evolve through a period of mo- 
saic gene expression, during which the cells may be prone to 
leukemic  transformation.  Malignant  transformation  of 
these progenitor cells could result in "mixed-lineage" leuke- 
mia. 
With the use of more comprehensive panels of MoAbs in 
immunophenotyping, increasing numbers of cases are be- 
ing characterized as  having "mixed-lineage" expression. My- 
eloid-associated antigen expression has been reported in up 
lymphoid-associated  antigen expression  in up to 60% of 
childhood  acute  myeloid  leukemia  (AML).'07,L86,2052206  In 
some cases of ALL, leukemic blasts coexpressed both T- and 
B-lineage-associated antigens (eg, CD2+/CD  19+ or CD7+/ 
CD  1  9+).15,207*209  Leukemic blasts coexpressing T-, B-,  and 
myeloid-associated antigens have also been  reported (Fig 
As mentioned earlier, none of the surface antigens stud- 
ied to date are lineage-specific.  For example, CD2, the E-ro- 
sette receptor, is expressed in almost one-half of the cases of 
acute promyelocytic  especially in the micro- 
granular variant.'"  CD4, another T-associated marker, is 
expressed  in  two-thirds  of  cases  of  M4  or  M5  leuke- 
mia205,21';  CD  19, a  B-lineage-associated  antigen,  can  be 
found on blast cells of three-fourths of cases of AML with 
the t(8;21)2L3,2L4;  whereas CD15 is expressed in two-thirds of 
ALL cases with the t(4;l 1).'43J44  Thus, more stringent crite- 
ria (ie, expression of two or more markers of another lin- 
eage) must be  applied  in  the diagnosis of mixed-lineage 
cases.'07 
Clinically, these cases can be subdivided into lymphoid 
antigen-positive  (Lyf) AML  or myeloid  antigen-positive 
(My+) ALL.'07  The Ly+ AML cases are characterized by 
FAB M 1 or M2 morphology, low levels of myeloperoxidase 
reactivity, and combined populations of myeloperoxidase- 
positive large blasts and small blasts, generally of hand- 
mirror morphology. 107~188~199  Importantly, some of these pa- 
tients  may  respond  to  lymphoid-directed  therapy 
(prednisone, vincristine, and L-asparaginase) after failing to 
respond on protocols for myeloid le~kemia.'~~,'~~ 
to 24% of childhood  ALL caSeS107,~86,19~,~95,200,201,203,204  and 
4).  107,206 
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Fig 4.  Three-dimensional graphic display of the CD34 (stem cell, x axis), CD33 (myeloid, y axis), and CD19 (6-lineage, z axis) markers 
coexpressed in a case of ALL. The analysis was performed with three-color flow cytometry (EPICS Elite, Hialeah, FL) using MoAbs conju- 
gated with Texas red (TR/CD19), fluorescein isothiocyanate (FITC/CD34), or  phycoerythrin (PE/CD33). The graphics were drawn with 
WinList (Verity. Topsham.  ME). Cell populations on plane A coexpressed CDl9/CD33, on plane 6 CD19/CD34, and on plane C CD34/ 
CD33: cell populations above plane C coexpressed all three antigens. Two-color analysis (not shown) showed coexpression of CD34/CD7, 
CD34/CD22 (6-lineage), and CD34/CDlO (CALLA). 
The My+ ALL cases have an increased frequency of FAB 
L2  morph~logy.'~'.~~  The prognostic  significance of  my- 
eloid-associated antigen expression in childhood ALL re- 
mains uncertain.  Although some studies have shown that 
expression of myeloid-associated antigens is a predictor of a 
poor outcome:00.20'  we and others were unable to confirm 
this result (Table 6).203*204  In our study, the estimated 3-year 
event-free survival (?SE) was 85% ? 6% for 50 patients with 
My+ ALL, as compared with 75% f  3% for the remaining 
260 patients.203  The reason for the difference in treatment 
outcome for My+ ALL in these studies is not entirely clear. 
We suggest that the prognostic importance of myeloid anti- 
gen expression, like most other clinical and laboratory fea- 
tures,  is treatment  dependent and can be abolished  with 
highly effective therapy. 
TREATMENT PLANNING  BY  IMMUNOPHENOTYPE 
Despite recent  improvements  in leukemia therapy, the 
immunologic subtypes of ALL still warrant consideration of 
different approaches to  treatment. For instance. the density 
of glucocorticoid  receptors in blast cells differs among the 
recognized phenotypes, in the descending order ofearly pre- 
B > pre-B > T-cell > B-cell  ALL.2'5*2'6  Although  a high 
number of receptors does not guarantee a response to  corti- 
costeroids, leukemic cells with few receptors, such as B cells, 
usually respond poorly to these  agent^.^" Moreover, cyclo- 
phosphamide  appears to be more effective for B-cell  and 
perhaps T-cell ALL than for the pre-B and early pre-B sub- 
classes. In fact. single-agent cyclophosphamide therapy has 
been curative in some patients with advanced B-cell malig- 
nancy.2'8 In mice, T-cell leukemia was shown to be more 
sensitive  to cyclophosphamide  and  cytarabine  than  to 
methotrexate and mer~aptopurine.~'~  A comparative clini- 
cal trial showed that a cyclophosphamide-cytarabine combi- 
nation could improve disease-free survival for children with 
T-cell ALL, but  not  for those with  non-T-cell  disease.220 
The difference in cellular proliferative rates (B-cell> T-cell 
> early pre-B ALL)"'  has also been used in planning treat- 
ment protocols, especially for B-cell and T-cell ALL. 
Currently, the POG  is the only major treatment group 
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that maintains separate treatment protocols for T-cell, B- 
cell, and other B-lineage (early pre-B and pre-B) ALLS. The 
justification  for this approach lies in the need to ensure a 
level of treatment intensity appropriate for the patient's risk 
category. For instance, by using antimetabolite-based ther- 
apy without cranial irradiation for the majority of children 
with B-progenitor ALL,162  POG investigators showed the 
feasibility of omitting highly toxic agents in regimens for a 
large subgroup of ALL patients. Organizing clinical trials on 
the basis of immunophenotype therefore provides an effi- 
cient way to assess the toxicityfefficacy ratio of treatment 
intensification or reduction. 
Recent improvements in assays of in vitro drug sensitivity 
may allow discrimination of cellular drug resistance profiles 
according to the biologic subtype of leukemia. In this re- 
gard, Pieters et a1222  found that blast cells from cases of T- 
cell, B-cell,  and CDlO-  early pre-B-cell  ALL were more 
resistant  to prednisolone,  daunorubicin,  and L-asparagi- 
nase, according to the MTT (3-[4,5-dimethylthiazol-2-y1]- 
2,Sdiphenyl tetrazolium bromide) assay. 
Finally, there is evidence to suggest that MoAb therapy 
directed to specific differentiation antigens might be useful 
in destroying leukemic cells. Since its first use in 1979,223 
well over 100 patients with a variety of hematologic malig- 
nancies have been treated by this method224;  however, nu- 
merous obstacles to serotherapy have been recognized, in- 
cluding antigen shedding, antigen modulation, nonspecific 
binding, heterogeneity of antigen expression, low cytotoxic- 
ity, and increased systemic  Although occasional 
complete responses have been rep~rted,~~'.~~~  the results of 
clinical trials  using unconjugated  MoAbs as serotherapy 
have been largely disappointing. A more promising avenue 
has been the use of antibody-toxin conjugates (immunotox- 
ins). In preliminary trials, these compounds have induced 
complete responses while causing several prominent side 
effects, most often capillary leak ~yndrome?~~-~~~  There is 
also evidence of synergy between immunotoxins and che- 
m~therapy,~~'  a combination that remains to be exploited 
clinically. Finally, MoAbs have been used to purge leuke- 
mic cells from harvested bone marrow before its reinfusion 
into patients undergoing autologous bone marrow trans- 
plantation .23  1,232 
IMMUNOPHENOTYPING IN  ADULT  ALL 
Patterns  of  immunologic  marker expression  have  not 
been as well characterized in adults as in children with ALL. 
Adult cases have a high frequency of T-cell and CD  10-  B- 
lineage ALL phenotypes, each occumng in approximately 
one-fifth of patients.  1653233-241  Only 2% to 4% of adults have a 
B-cell phen~type.~~~,~~~,~~~  B  ecause cIg is not routinely  as- 
sayed in adult series, the frequency of the pre-B immuno- 
phenotype in this age group is unknown. As in childhood 
cases, T-cell ALL in adults is characterized by male predom- 
inence, high leukocyte count, an increased frequency of an- 
terior mediastinal mass, and CDlO positivity in approxi- 
mately 40% of  Adult CD  10- B-lineage ALL has 
been associated with a poor prognosis, whereas several in- 
vestigators  reported  a  relatively  favorable  prognosis  for 
adult T-cell ALL, using cytarabine in combination with ei- 
ther cyclophosphamide or teniposide.234,236,237,240  Little is 
known  about  prognostic  factors in individual  immuno- 
phenotypic subtypes of  adult ALL.  In one study, a high 
leukocyte count conferred a poor prognosis in B-lineage 
ALL but not in T-cell cases.24o 
My+ ALL appears to be more common in adults than in 
children. In six combined series of  adult ALL cases,  113 
(33.3%) of  339 patients had lymphoblasts that expressed 
one or more myeloid  Even when 
more stringent criteria were used, the diagnosis of My+  ALL 
could be made in up to 18%  of ad~lts,~~'~'~~  in contrast to 6% 
to 8% of ~hildren.''~,~~  An increased frequency of L2 mor- 
phology, azurophilic cytoplasmic granules, acid a-naphthyl 
acetate esterase positivity, and unusual morphology (mono- 
cytoid features and cytoplasmic buds) has been observed for 
blast cells of My+ ALL cases in  adult^.'^^,'^^ In most adult 
series, My+ ALL was associated with a lower remission in- 
duction rate and shorter survival 
DETECTION  OF  MINIMAL RESIDUAL LEUKEMIA 
Conventional  methods for detecting residual leukemia, 
such as cell morphologic,242  and Southern 
analyses, have sensitivities between  1% and 5%. 
Gene  amplification  by  the  polymerase  chain  reaction 
(PCR) offers greater  sensitivity  than do other available 
methods.248-257  Nonetheless, all PCR methods have limita- 
tions,  including amplification of genome segments from 
nonviable  or  nondividing  leukemic  cells.  The  double- 
marker immunofluorescence assay is another sensitive al- 
ternative for detecting minimal residual leukemia at levels 
below 1  0-4 malignant ce11s.255,258-260  Th'  is method is based on 
the premise that certain combinations of differentiation an- 
tigens are expressed on leukemic blasts or normal cells con- 
fined to extramedullary sites (eg, thymus), but are absent 
from normal peripheral blood and bone marrow. But this 
method can be applied only to the 30% to 40% of ALL cases 
with phenotypic features that are extremely rare or absent in 
normal bone marrow. Thus, all approaches to the detection 
of minimal residual leukemia carry certain limitations and 
specific advantages, and should be viewed as complemen- 
tary to each other. Although the clinical utility of routine 
screening for residual ALL remains to be determined in 
prospective trials, the expectation is that early detection of 
residual leukemia will permit beneficial treatment modifica- 
tions before relapse. 
bIot245-247 
SUMMARY 
Immunologic marker studies of the lymphoid leukemias 
have greatly improved the precision of diagnosis of these 
disorders by providing specific information  regarding the 
lineage and stage of maturation of the malignant cells. Such 
studies have also enhanced  our understanding  of normal 
lymphocyte development, permitting reproducible identifi- 
cation of lymphoid cells in discrete developmental stages. 
By elucidating the functions of lymphoid cell differentiation 
antigens, it has been possible to gain insight into the signal 
transduction  mechanisms  by  which  these  cells  interact 
among themselves and with other cell types. Similar studies 
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have shown that ALL is an immunophenotypically hetero- 
geneous disease with clinically important subtypes repre- 
senting clonal expansions of lymphoblasts at different stages 
of maturation. Furthermore, successful correlation of im- 
munophenotype with certain karyotypic and molecular ab- 
normalities, which appear to underlie most or all leukemias, 
were  made  possible  by  the  inclusion  of  immunologic 
marker assessment. Interestingly, many ofthese phenotype- 
related abnormalities have involved either the Ig or TCR 
genes, thus providing additional clues to the mechanisms of 
leukemogenesis. 
Knowledge of the immunologic features of leukemic cells 
has been essential for the generation of phenotype-specific 
response data in the context of modern therapy for ALL. 
With wider use of intensive treatment, the traditional prog- 
nostic distinctions among immunophenotypes have begun 
to disappear; however, certain classes of agents have more 
favorable toxicity/efficacy ratios  against  some  immuno- 
phenotypes than others, justifying continued efforts to tar- 
get  therapy  by  immunologic  species of  ALL.  Antibody- 
toxin conjugates, or immunotoxins,  have induced complete 
responses in preliminary trials and may prove clinically use- 
ful, perhaps  in  combination  with chemotherapy, if their 
toxic side effects can be controlled. Finally, immunologic 
markers may serve as sensitive targets for the detection of 
minimal residual disease; the clinical usefulness of this ap- 
proach will depend on prospective comparisons with molec- 
ular methods. 
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